PT3087089T - Terapêutica de multiprotease para a dor crónica - Google Patents

Terapêutica de multiprotease para a dor crónica

Info

Publication number
PT3087089T
PT3087089T PT148211717T PT14821171T PT3087089T PT 3087089 T PT3087089 T PT 3087089T PT 148211717 T PT148211717 T PT 148211717T PT 14821171 T PT14821171 T PT 14821171T PT 3087089 T PT3087089 T PT 3087089T
Authority
PT
Portugal
Prior art keywords
multiprotease
therapeutics
chronic pain
pain
chronic
Prior art date
Application number
PT148211717T
Other languages
English (en)
Portuguese (pt)
Inventor
Oliver Dolly James
Wang Jiafu
Meng Jianghui
Original Assignee
Univ Dublin City
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Dublin City filed Critical Univ Dublin City
Publication of PT3087089T publication Critical patent/PT3087089T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PT148211717T 2013-12-23 2014-12-19 Terapêutica de multiprotease para a dor crónica PT3087089T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361920053P 2013-12-23 2013-12-23
US14/244,162 US9216210B2 (en) 2013-12-23 2014-04-03 Multiprotease therapeutics for chronic pain

Publications (1)

Publication Number Publication Date
PT3087089T true PT3087089T (pt) 2018-05-28

Family

ID=53398919

Family Applications (1)

Application Number Title Priority Date Filing Date
PT148211717T PT3087089T (pt) 2013-12-23 2014-12-19 Terapêutica de multiprotease para a dor crónica

Country Status (13)

Country Link
US (2) US9216210B2 (enExample)
EP (1) EP3087089B1 (enExample)
JP (1) JP6378772B2 (enExample)
KR (1) KR101900582B1 (enExample)
CN (2) CN105916875A (enExample)
AU (1) AU2014372689B2 (enExample)
CA (1) CA2934986C (enExample)
DK (1) DK3087089T3 (enExample)
ES (1) ES2671493T3 (enExample)
PL (1) PL3087089T3 (enExample)
PT (1) PT3087089T (enExample)
WO (1) WO2015097087A1 (enExample)
ZA (1) ZA201605051B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100266638A1 (en) 2004-02-26 2010-10-21 Allergan, Inc. Headache treatment method
US9216210B2 (en) * 2013-12-23 2015-12-22 Dublin City University Multiprotease therapeutics for chronic pain
RU2746736C2 (ru) 2015-03-26 2021-04-20 Президент Энд Феллоуз Оф Гарвард Колледж Сконструированный ботулинический нейротоксин
GB201517450D0 (en) * 2015-10-02 2015-11-18 Ipsen Biopharm Ltd Method
GB201607901D0 (en) * 2016-05-05 2016-06-22 Ipsen Biopharm Ltd Chimeric neurotoxins
EP3504226A1 (en) 2016-08-24 2019-07-03 President and Fellows of Harvard College Engineered botulinum neurotoxin
CN109790204A (zh) * 2016-09-29 2019-05-21 益普生生物制药有限公司 杂合神经毒素
US11707510B2 (en) * 2018-02-16 2023-07-25 Preclinics Discovery Gmbh Nucleic acid-based botulinum neurotoxin for therapeutic use
GB201815844D0 (en) * 2018-09-28 2018-11-14 Ipsen Biopharm Ltd Therapeutic & comestic uses of botulinum neurotoxin serotype e
FR3114739B1 (fr) * 2020-10-06 2022-08-26 Centre Nat Rech Scient Nouveaux peptoides et leur utilisation dans la prevention ou le traitement de la douleur chronique
WO2023105289A1 (en) 2021-12-06 2023-06-15 Dublin City University Methods and compositions for the treatment of pain

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2341140T3 (es) 1993-06-10 2010-06-15 Allergan, Inc. Tratamiento de trastornos y afecciones neuromusculares con un seropositivo botulinico diferente.
US5437291A (en) 1993-08-26 1995-08-01 Univ Johns Hopkins Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction
US6974578B1 (en) 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
US20040126396A1 (en) 1993-12-28 2004-07-01 Allergan, Inc. Botulinum toxin treatment for strabismus
US8187612B2 (en) 1993-12-28 2012-05-29 Allergan, Inc. Use of the neurotoxic component of a botulinum toxin for treating a spastic muscle
ATE215832T1 (de) 1994-05-09 2002-04-15 William J Binder Botulinumtoxin zur reduktion von migraine - kopfschmerzen
US5670484A (en) 1994-05-09 1997-09-23 Binder; William J. Method for treatment of skin lesions associated with cutaneous cell-proliferative disorders
DE69511860T2 (de) 1994-05-31 2000-02-10 Allergan, Inc. Modifizierung von clostridium-toxinen und ihre anwendung als transport proteine
GB9508204D0 (en) 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
GB9617671D0 (en) 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
US7192596B2 (en) 1996-08-23 2007-03-20 The Health Protection Agency Ipsen Limited Recombinant toxin fragments
US6063768A (en) 1997-09-04 2000-05-16 First; Eric R. Application of botulinum toxin to the management of neurogenic inflammatory disorders
GB9721189D0 (en) 1997-10-08 1997-12-03 Speywood Lab The Limited Analgesic conjugates
JP2002512977A (ja) 1998-04-29 2002-05-08 アラーガン・セイルズ・インコーポレイテッド クロストリディウム属細菌の神経毒の作用を延長させる組成物および方法
GB9907429D0 (en) 1999-03-31 1999-05-26 Microbiological Res Authority Modulation of C-fibre activity
US6776990B2 (en) 1999-04-08 2004-08-17 Allergan, Inc. Methods and compositions for the treatment of pancreatitis
US6767544B2 (en) 2002-04-01 2004-07-27 Allergan, Inc. Methods for treating cardiovascular diseases with botulinum toxin
US6358917B1 (en) 1999-08-24 2002-03-19 Jean D. A. Carruthers Cosmetic use of botulinum toxin for treatment of downturned mouth
US20080032931A1 (en) * 1999-08-25 2008-02-07 Steward Lance E Activatable clostridial toxins
EP2267008B1 (en) * 1999-08-25 2014-07-02 Allergan, Inc. Activatable recombinant neurotoxins
US7740868B2 (en) * 1999-08-25 2010-06-22 Allergan, Inc. Activatable clostridial toxins
US6113915A (en) 1999-10-12 2000-09-05 Allergan Sales, Inc. Methods for treating pain
US6265379B1 (en) 1999-10-13 2001-07-24 Allergan Sales, Inc. Method for treating otic disorders
US6139845A (en) 1999-12-07 2000-10-31 Allergan Sales, Inc. Method for treating cancer with a neurotoxin
US7838008B2 (en) 1999-12-07 2010-11-23 Allergan, Inc. Methods for treating diverse cancers
US6337075B1 (en) 2000-01-11 2002-01-08 Allergan Sales, Inc. Methods for treating diabetes
US6143306A (en) 2000-01-11 2000-11-07 Allergan Sales, Inc. Methods for treating pancreatic disorders
US6641820B1 (en) 2000-01-19 2003-11-04 Allergan, Inc. Clostridial toxin derivatives and methods to treat pain
US6524580B1 (en) 2000-02-15 2003-02-25 Allergan Sales, Inc. Method for treating thyroid disorders
US6464986B1 (en) 2000-04-14 2002-10-15 Allegan Sales, Inc. Method for treating pain by peripheral administration of a neurotoxin
US6299893B1 (en) 2000-04-17 2001-10-09 Marvin Schwartz Method to reduce hair loss and stimulate hair regrowth
US6565870B1 (en) 2000-04-28 2003-05-20 Allergan, Inc. Methods for treating bone tumors
US6306403B1 (en) 2000-06-14 2001-10-23 Allergan Sales, Inc. Method for treating parkinson's disease with a botulinum toxin
US6423319B1 (en) 2000-10-04 2002-07-23 Allergan Sales, Inc. Methods for treating muscle injuries
US6827931B1 (en) 2000-10-20 2004-12-07 Allergan, Inc. Method for treating endocrine disorders
US20020127247A1 (en) 2000-11-17 2002-09-12 Allergen Sales, Inc. Modified clostridial neurotoxins with altered biological persistence
US7273722B2 (en) 2000-11-29 2007-09-25 Allergan, Inc. Neurotoxins with enhanced target specificity
GB0111146D0 (en) 2001-05-04 2001-06-27 Imp College Innovations Ltd Methods
US6623742B2 (en) 2001-09-17 2003-09-23 Allergan, Inc. Methods for treating fibromyalgia
US7255866B2 (en) 2001-09-17 2007-08-14 Allergan, Inc. Botulinum toxin therapy for fibromyalgia
US6921538B2 (en) 2002-05-10 2005-07-26 Allergan, Inc. Therapeutic treatments for neuropsychiatric disorders
MXPA05003936A (es) 2002-10-15 2005-06-17 Allergan Inc Terapias y procedimientos odontologicos con toxina botulinica.
US7238357B2 (en) 2002-11-05 2007-07-03 Allergan, Inc. Methods for treating ulcers and gastroesophageal reflux disease
US8071550B2 (en) 2003-03-03 2011-12-06 Allergan, Inc. Methods for treating uterine disorders
US6838434B2 (en) 2003-05-02 2005-01-04 Allergan, Inc. Methods for treating sinus headache
US7220422B2 (en) 2003-05-20 2007-05-22 Allergan, Inc. Methods and compositions for treating eye disorders
US20040253274A1 (en) 2003-06-11 2004-12-16 Allergan, Inc. Use of a clostridial toxin to reduce appetite
US20050169942A1 (en) 2003-10-07 2005-08-04 Allergan, Inc. Novel DNA sequences of the botulinum neurotoxin complex of Clostridium botulinum type A-Hall (Allergan) strain for production of therapeutics
US7825233B2 (en) 2004-06-30 2010-11-02 Allergan, Inc. Optimizing expression of active Botulinum Toxin type E
US7514088B2 (en) 2005-03-15 2009-04-07 Allergan, Inc. Multivalent Clostridial toxin derivatives and methods of their use
US20060024331A1 (en) 2004-08-02 2006-02-02 Ester Fernandez-Salas Toxin compounds with enhanced membrane translocation characteristics
WO2006069429A1 (en) 2004-09-30 2006-07-06 Pro-Adn Diagnostic Wnt4 in supporting lymphopoiesis
EP1861419B1 (en) 2005-03-15 2011-06-29 Allergan, Inc. Modified clostridial toxins with enhanced targeting capabilities for endogenous clostridial toxin receptor systems
GB0610868D0 (en) 2006-06-01 2006-07-12 Syntaxin Ltd Treatment of pain
BRPI0915142A8 (pt) * 2008-06-12 2018-01-02 Syntaxin Ltd Polipeptídeos, ácido nucleico e usos dos mesmos
ES2592314T3 (es) 2008-08-29 2016-11-29 Merz Pharma Gmbh & Co. Kgaa Neurotoxinas clostridiales con persistencia modificada
JP5826635B2 (ja) 2009-03-13 2015-12-02 アラーガン、インコーポレイテッドAllergan,Incorporated 免疫系調節エンドペプチターゼ活性アッセイ
WO2010120766A1 (en) * 2009-04-14 2010-10-21 Mcw Research Foundation, Inc. Engineered botulinum neurotoxin
JP2013514091A (ja) 2009-12-16 2013-04-25 アラーガン、インコーポレイテッド 組込型プロテアーゼ切断部位結合ドメインを含む改変クロストリジウム毒素
BR112012029666A2 (pt) 2010-05-20 2020-10-06 Allergan, Inc. toxinas clostridiais degradáveis
US20130116794A1 (en) 2010-08-04 2013-05-09 Shaul Shohat Shoulder implant
US9005628B2 (en) 2012-10-04 2015-04-14 Dublin City University Biotherapy for pain
US20140177773A1 (en) * 2012-12-20 2014-06-26 Maria Christine KRETZING Control rod drive apparatus utilizing alloys with low to zero cobalt content
WO2014113539A1 (en) * 2013-01-16 2014-07-24 Bal Ram Singh Botulinum chimera compositions for axonal regenerative therapy during spinal cord injury
US9447405B2 (en) * 2013-03-08 2016-09-20 Wisconsin Alumni Research Foundation Regulation of specific spinal neurons regulating pain transmission via chimeric toxins
US9216210B2 (en) * 2013-12-23 2015-12-22 Dublin City University Multiprotease therapeutics for chronic pain
WO2016180533A1 (en) * 2015-05-12 2016-11-17 Merz Pharma Gmbh & Co. Kgaa Novel recombinant clostridial neurotoxins with increased duration of effect

Also Published As

Publication number Publication date
CN105916875A (zh) 2016-08-31
EP3087089A1 (en) 2016-11-02
JP6378772B2 (ja) 2018-08-22
WO2015097087A1 (en) 2015-07-02
CA2934986C (en) 2019-08-20
ZA201605051B (en) 2017-09-27
US9216210B2 (en) 2015-12-22
AU2014372689B2 (en) 2018-02-01
CA2934986A1 (en) 2015-07-02
KR20160096201A (ko) 2016-08-12
US20160230159A1 (en) 2016-08-11
US10457927B2 (en) 2019-10-29
US20150174217A1 (en) 2015-06-25
KR101900582B1 (ko) 2018-09-19
AU2014372689A1 (en) 2016-07-21
ES2671493T3 (es) 2018-06-06
DK3087089T3 (en) 2018-06-06
PL3087089T3 (pl) 2018-10-31
EP3087089B1 (en) 2018-02-21
JP2017501715A (ja) 2017-01-19
CN112708630A (zh) 2021-04-27

Similar Documents

Publication Publication Date Title
GB2508037B (en) Chair
HUE052860T2 (hu) Elpárologtató
AU355185S (en) Chair
ZA201605051B (en) Multiprotease therapeutics for chronic pain
SI2941135T1 (sl) Tobačni nadomestek
GB201308440D0 (en) Therapeutic
AU351025S (en) Chair
GB2520812B (en) Lift-recliner chair
IL241190B (en) 7smad–ptd medical
SG2013084207A (en) Aptamers
GB201305118D0 (en) Blends
GB201318668D0 (en) Sonosensitive therapeutic
GB201308122D0 (en) Chair
GB201309967D0 (en) Therapeutic combinations
GB201310194D0 (en) DAB interface
GB201300932D0 (en) Therapeutics
GB201320894D0 (en) CSF-1 Therapeutics
HU4880U (hu) Inhalátor
GB201303537D0 (en) CSF-1 based therapeutics
GB201303366D0 (en) CSF-1 based therapeutics
GB201322021D0 (en) Aptamers
AU352785S (en) Chair
AU352787S (en) Chair
AU352786S (en) Chair
AU352853S (en) Chair